Capio Biosciences is pleased to announce receipt of an official Notice of Allowance for patent application # 10-2017-7035887 - "Method for monitoring efficacy of a cancer therapy using Circulating Tumor Cells as a biomarker” from the Korean Intellectual Property Office (KIPO). This patent, exclusively licensed to Capio Biosciences by the Board of Trustees of the University of Illinois; and the University of North Carolina at Chapel Hill, further strengthens the intellectual property portfolio of Capio Biosciences, and is another step toward clinical translation of CapioCyte™ technology.
